Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Hypertension

Free Subscription Articles published in Eur J Pharmacol Retrieve available abstracts of 73 articles: HTML format

Single Articles

April 2024
1. YAMAMURA A, Fujiwara M, Kawade A, Amano T, et al
   Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension.
   Eur J Pharmacol. 2024;973:176564.
   PubMed     Abstract available
   
   
   
2. LAXMI, Golmei P, Srivastava S, Kumar S, et al
   Single nucleotide polymorphism-based biomarker in primary hypertension.
   Eur J Pharmacol. 2024;972:176584.
   PubMed     Abstract available
   
   
   
3. LI Q, Cao H, Xu X, Chen Y, et al
   Resveratrol attenuates cyclosporin A-induced upregulation of the thromboxane A(2) receptor and hypertension via the AMPK/SIRT1 and MAPK/NF-kappaB pathways in the rat mesenteric artery.
   Eur J Pharmacol. 2024;972:176543.
   PubMed     Abstract available
   
   
   March 2024
4. BENCZE M, Boros A, Behuliak M, Vavrinova A, et al
   Changes in cardiovascular autonomic control induced by chronic inhibition of acetylcholinesterase during pyridostigmine or donepezil treatment of spontaneously hypertensive rats.
   Eur J Pharmacol. 2024 Mar 25:176526. doi: 10.1016/j.ejphar.2024.176526.
   PubMed     Abstract available
   
   
   
5. WANG J, Liu C, Huang SS, Wang HF, et al
   Functions and novel regulatory mechanisms of key glycolytic enzymes in pulmonary arterial hypertension.
   Eur J Pharmacol. 2024;970:176492.
   PubMed     Abstract available
   
   
   
6. CHEN Y, Liu J, Zhang Q, Chai L, et al
   Activation of CaMKII/HDAC4 by SDF1 contributes to pulmonary arterial hypertension via stabilization Runx2.
   Eur J Pharmacol. 2024;970:176483.
   PubMed     Abstract available
   
   
   
7. TANNA S, Doshi G, Godad A
   siRNA as potential therapeutic strategy for hypertension.
   Eur J Pharmacol. 2024;969:176467.
   PubMed     Abstract available
   
   
   February 2024
8. FU LY, Yang Y, Tian H, Jia XY, et al
   Central administration of AICAR attenuates hypertension via AMPK/Nrf2 pathway in the hypothalamic paraventricular nucleus of hypertensive rats.
   Eur J Pharmacol. 2024 Feb 8:176373. doi: 10.1016/j.ejphar.2024.176373.
   PubMed     Abstract available
   
   
   January 2024
9. LIU Q, Luo Q, Zhong B, Tang K, et al
   Salidroside attenuates myocardial remodeling in DOCA-salt-induced mice by inhibiting the endothelin 1 and PI3K/AKT/NFkappaB signaling pathways.
   Eur J Pharmacol. 2024;962:176236.
   PubMed     Abstract available
   
   
   
10. LI MH, Liu X, Xie YL, Tang XG, et al
    Sodium butyrate alleviates right ventricular hypertrophy in pulmonary arterial hypertension by inhibiting H19 and affecting the activation of let-7g-5p/IGF1 receptor/ERK.
    Eur J Pharmacol. 2024 Jan 2:176315. doi: 10.1016/j.ejphar.2024.176315.
    PubMed     Abstract available
    
    
    December 2023
11. FAN Q, Wu G, Chen M, Luo G, et al
    Cediranib ameliorates portal hypertensive syndrome via inhibition of VEGFR-2 signaling in cirrhotic rats.
    Eur J Pharmacol. 2023 Dec 27:176278. doi: 10.1016/j.ejphar.2023.176278.
    PubMed     Abstract available
    
    
    
12. QAYYUM MI, Ullah S, Rashid U, Sadiq A, et al
    N-phenyl and N-benzyl substituted succinimides: Preclinical evaluation for their antihypertensive effect and underlying mechanism.
    Eur J Pharmacol. 2023 Dec 22:176195. doi: 10.1016/j.ejphar.2023.176195.
    PubMed     Abstract available
    
    
    
13. HUANG J, Xie Y, Chen B, Xia Y, et al
    GPR146 regulates pulmonary vascular remodeling by promoting pulmonary artery smooth muscle cell proliferation through 5-lipoxygenase.
    Eur J Pharmacol. 2023;961:176123.
    PubMed     Abstract available
    
    
    
14. LI D, Chen Y, Wang Y, Liu J, et al
    NAMPT mediates PDGF-induced pulmonary arterial smooth muscle cell proliferation by TLR4/NF-kappaB/PLK4 signaling pathway.
    Eur J Pharmacol. 2023;961:176151.
    PubMed     Abstract available
    
    
    
15. SILVA-VELASCO DL, Hong E, Beltran-Ornelas JH, Sanchez-Lopez A, et al
    Hydrogen sulfide ameliorates hypertension and vascular dysfunction induced by insulin resistance in rats by reducing oxidative stress and activating eNOS.
    Eur J Pharmacol. 2023 Dec 12:176266. doi: 10.1016/j.ejphar.2023.176266.
    PubMed     Abstract available
    
    
    
16. MANEESAI P, Potue P, Khamseekaew J, Sangartit W, et al
    Kaempferol protects against cardiovascular abnormalities induced by nitric oxide deficiency in rats by suppressing the TNF-alpha pathway.
    Eur J Pharmacol. 2023;960:176112.
    PubMed     Abstract available
    
    
    
17. XU Q, Zhuo K, Zhang X, Zhen Y, et al
    The role of angiotensin II activation of yes-associated protein/PDZ-binding motif signaling in hypertensive cardiac and vascular remodeling.
    Eur J Pharmacol. 2023 Dec 5:176252. doi: 10.1016/j.ejphar.2023.176252.
    PubMed     Abstract available
    
    
    November 2023
18. VAN DORST DCH, Mirabito Colafella KM, van Veghel R, Garrelds IM, et al
    Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment.
    Eur J Pharmacol. 2023 Nov 27:176199. doi: 10.1016/j.ejphar.2023.176199.
    PubMed     Abstract available
    
    
    
19. HO CY, Sun GC, Lin YT, Wong TY, et al
    Microglial activation and toll-like receptor 4-Dependent regulation of angiotensin II type I receptor-mu-opioid receptor 1 heterodimerization and hypertension in fructose-fed rats.
    Eur J Pharmacol. 2023 Nov 21:176171. doi: 10.1016/j.ejphar.2023.176171.
    PubMed     Abstract available
    
    
    
20. MATSUMOTO T, Taguchi K, Kobayashi T
    Role of TRPV4 on vascular tone regulation in pathophysiological states.
    Eur J Pharmacol. 2023;959:176104.
    PubMed     Abstract available
    
    
    
21. EDOSUYI O, Igbe I, Oyekan A
    Fumarate and its downstream signalling pathways in the cardiorenal system: Recent insights and novel expositions in the etiology of hypertension.
    Eur J Pharmacol. 2023 Nov 7:176186. doi: 10.1016/j.ejphar.2023.176186.
    PubMed     Abstract available
    
    
    
22. YI Y, Tianxin Y, Zhangchi L, Cui Z, et al
    Pinocembrin attenuates susceptibility to atrial fibrillation in rats with pulmonary arterial hypertension.
    Eur J Pharmacol. 2023;960:176169.
    PubMed     Abstract available
    
    
    October 2023
23. KONG S, Yu J, Li HF, Xie YL, et al
    A ring N(CH(3))(2)-based derivative of resveratrol inhibits pulmonary vascular remodeling in hypoxia pulmonary hypertension.
    Eur J Pharmacol. 2023 Oct 9:176077. doi: 10.1016/j.ejphar.2023.176077.
    PubMed     Abstract available
    
    
    
24. CHAI L, Wang Q, Wang Y, Li D, et al
    Downregulation of PDCD4 through STAT3/ATF6/autophagy mediates MIF-induced PASMCs proliferation/migration and vascular remodeling.
    Eur J Pharmacol. 2023;956:175968.
    PubMed     Abstract available
    
    
    
25. GUTIERREZ A, Gomez Del Val A, Contreras C, Olmos L, et al
    Calcium handling coupled to the endothelin ET(A) and ET(B) receptor-mediated vasoconstriction in resistance arteries: Differential regulation by PI3K, PKC and RhoK.
    Eur J Pharmacol. 2023;956:175948.
    PubMed     Abstract available
    
    
    September 2023
26. NOAH AA, El-Mezayen NS, El-Ganainy SO, Darwish IE, et al
    Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl(4)-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-beta and gal-1/NRP-1/VEGFR2 pathways.
    Eur J Pharmacol. 2023 Sep 26:176066. doi: 10.1016/j.ejphar.2023.176066.
    PubMed     Abstract available
    
    
    
27. VALOVIC P, Behuliak M, Vaneckova I, Zicha J, et al
    Impaired vascular beta-adrenergic relaxation in spontaneously hypertensive rats: The differences between conduit and resistance arteries.
    Eur J Pharmacol. 2023 Sep 12:176045. doi: 10.1016/j.ejphar.2023.176045.
    PubMed     Abstract available
    
    
    August 2023
28. V B, Wright G, Sundhar M, Ravikumar TS, et al
    Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF.
    Eur J Pharmacol. 2023 Aug 25:176010. doi: 10.1016/j.ejphar.2023.176010.
    PubMed     Abstract available
    
    
    June 2023
29. CHEN M, Hu Q, Wang S, Tao L, et al
    1,8-Cineole ameliorates endothelial injury and hypertension induced by L-NAME through regulation of autophagy via PI3K/mTOR signaling pathway.
    Eur J Pharmacol. 2023 Jun 26:175863. doi: 10.1016/j.ejphar.2023.175863.
    PubMed     Abstract available
    
    
    
30. DOURADO TMH, Assis VO, Awata WMC, de Mello MMB, et al
    Mineralocorticoid receptors contribute to ethanol-induced vascular hypercontractility through reactive oxygen species generation and up-regulation of cyclooxygenase 2.
    Eur J Pharmacol. 2023;949:175723.
    PubMed     Abstract available
    
    
    May 2023
31. LI Q, Fang Y, Peng DW, Li LA, et al
    Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
    Eur J Pharmacol. 2023 May 12:175754. doi: 10.1016/j.ejphar.2023.175754.
    PubMed     Abstract available
    
    
    
32. ABDULKAREEM AO, Tiwari P, Lone ZR, Iqbal H, et al
    Corrigendum to "Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension" [Eur. J. Pharmacol. 943 (2023) 175558].
    Eur J Pharmacol. 2023 May 3:175750. doi: 10.1016/j.ejphar.2023.175750.
    PubMed    
    
    
    March 2023
33. MARTINEZ VR, Martins Lima A, Stergiopulos N, Velez Rueda JO, et al
    Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy.
    Eur J Pharmacol. 2023 Mar 14:175654. doi: 10.1016/j.ejphar.2023.175654.
    PubMed     Abstract available
    
    
    
34. ABDELAZEEM H, Tu L, Thuillet R, Ottaviani M, et al
    AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery.
    Eur J Pharmacol. 2023 Mar 11:175579. doi: 10.1016/j.ejphar.2023.175579.
    PubMed     Abstract available
    
    
    February 2023
35. ZHAN Q, Zhao J, Liu L, Wang B, et al
    Integrated network pharmacology and molecular docking analyses of the mechanisms underlying the antihypertensive effects of lotusine.
    Eur J Pharmacol. 2023 Feb 28:175622. doi: 10.1016/j.ejphar.2023.175622.
    PubMed     Abstract available
    
    
    
36. JIANG Y, Huang J, Xia Y, Sun Z, et al
    Hypoxia activates GPR146 which participates in pulmonary vascular remodeling by promoting pyroptosis of pulmonary artery endothelial cells.
    Eur J Pharmacol. 2023;941:175502.
    PubMed     Abstract available
    
    
    
37. HERTEL M, Preissner S, Gohlke BO, Kuebler WM, et al
    Real-world evidence for beneficial effects of dipyrone in 4,278 patients with pulmonary hypertension - Analysis of the risk of ventilation, hospitalization, and agranulocytosis.
    Eur J Pharmacol. 2023 Feb 6:175567. doi: 10.1016/j.ejphar.2023.175567.
    PubMed     Abstract available
    
    
    January 2023
38. ABDULKAREEM AO, Tiwari P, Lone ZR, Iqbal H, et al
    Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension.
    Eur J Pharmacol. 2023 Jan 30:175558. doi: 10.1016/j.ejphar.2023.175558.
    PubMed     Abstract available
    
    
    
39. NIE X, Wu Z, Shang J, Zhu L, et al
    Curcumol suppresses endothelial-to-mesenchymal transition via inhibiting the AKT/GSK3beta signaling pathway and alleviates pulmonary arterial hypertension in rats.
    Eur J Pharmacol. 2023 Jan 24:175546. doi: 10.1016/j.ejphar.2023.175546.
    PubMed     Abstract available
    
    
    December 2022
40. ZENG Z, Zhou X, Zhu Y, Huang X, et al
    Kruppel-like Factor 7 inhibits proliferation and migration of pulmonary smooth muscle cells via p21 activation.
    Eur J Pharmacol. 2022;940:175473.
    PubMed     Abstract available
    
    
    September 2022
41. CHEN S, Sun P, Li Y, Shen W, et al
    Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension.
    Eur J Pharmacol. 2022 Sep 10:175262. doi: 10.1016/j.ejphar.2022.175262.
    PubMed     Abstract available
    
    
    
42. YAN J, Honglei Y, Yun W, Sheng D, et al
    Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway.
    Eur J Pharmacol. 2022 Sep 7:175254. doi: 10.1016/j.ejphar.2022.175254.
    PubMed     Abstract available
    
    
    August 2022
43. GHAFOURI-FARD S, Shirvani-Farsani Z, Hussen BM, Taheri M, et al
    The key roles of non-coding RNAs in the pathophysiology of hypertension.
    Eur J Pharmacol. 2022 Aug 19:175220. doi: 10.1016/j.ejphar.2022.175220.
    PubMed     Abstract available
    
    
    
44. TURHAN K, Alan E, Yetik-Anacak G, Sevin G, et al
    H2S releasing sodium sulfide protects against pulmonary hypertension by improving vascular responses in monocrotaline-induced pulmonary hypertension.
    Eur J Pharmacol. 2022 Aug 5:175182. doi: 10.1016/j.ejphar.2022.175182.
    PubMed     Abstract available
    
    
    July 2022
45. KODAMA T, Otani K, Okada M, Yamawaki H, et al
    Eukaryotic elongation factor 2 kinase inhibitor, A484954 inhibits perivascular sympathetic nerve stimulation-induced vasoconstriction in isolated renal artery.
    Eur J Pharmacol. 2022;926:175042.
    PubMed     Abstract available
    
    
    
46. WANG C, Han L, Wang T, Wang Y, et al
    Cyclosporin A up-regulated thromboxane A2 receptor through activation of MAPK and NF-kappaB pathways in rat mesenteric artery.
    Eur J Pharmacol. 2022;926:175034.
    PubMed     Abstract available
    
    
    
47. IQBAL H, Yadav P, Verma AK, Mishra D, et al
    Anti-inflammatory, anti-oxidant and cardio-protective properties of novel fluorophenyl benzimidazole in L-NAME-induced hypertensive rats.
    Eur J Pharmacol. 2022 Jul 2:175132. doi: 10.1016/j.ejphar.2022.175132.
    PubMed     Abstract available
    
    
    June 2022
48. ZHAO X, Li L, Li S, Liu J, et al
    Diammonium glycyrrhizinate ameliorates portal hypertension by regulating portal macrophage oxidation and superoxide dismutase 3.
    Eur J Pharmacol. 2022 Jun 20:175115. doi: 10.1016/j.ejphar.2022.175115.
    PubMed     Abstract available
    
    
    
49. LI XT, Zhang YP, Zhang MW, Zhang ZZ, et al
    Sirtuin 7 serves as a promising therapeutic target for cardiorenal diseases.
    Eur J Pharmacol. 2022;925:174977.
    PubMed     Abstract available
    
    
    May 2022
50. LI L, Su XL, Bai TT, Qin W, et al
    New paeonol derivative C302 reduces hypertension in spontaneously hypertensive rats through endothelium-dependent and endothelium-independent vasodilation.
    Eur J Pharmacol. 2022 May 27:175057. doi: 10.1016/j.ejphar.2022.175057.
    PubMed     Abstract available
    
    
    
51. BANKS TE, Rajapaksha M, Zhang LH, Bai F, et al
    Suppression of angiotensin II-activated NOX4/NADPH oxidase and mitochondrial dysfunction by preserving glucagon-like peptide-1 attenuates myocardial fibrosis and hypertension.
    Eur J Pharmacol. 2022 May 26:175048. doi: 10.1016/j.ejphar.2022.175048.
    PubMed     Abstract available
    
    
    
52. JOO TURONI CM, Maranon RO, Alberstein RA, Sanchez RS, et al
    A novel endothelium-independent effect of insulin on basal vascular tone in cafeteria diet-induced hypertensive rats.
    Eur J Pharmacol. 2022;925:174997.
    PubMed     Abstract available
    
    
    March 2022
53. SHIMIZU S, Nagao Y, Kurabayashi A, Shimizu T, et al
    Effects of losartan on bladder dysfunction due to aging-related severe hypertension in rats.
    Eur J Pharmacol. 2022 Mar 22:174911. doi: 10.1016/j.ejphar.2022.174911.
    PubMed     Abstract available
    
    
    January 2022
54. CHEN D, Yuan T, Chen Y, Zhang H, et al
    DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
    Eur J Pharmacol. 2022 Jan 26:174779. doi: 10.1016/j.ejphar.2022.174779.
    PubMed     Abstract available
    
    
    December 2021
55. DIAS CJ, Costa HA, Alves Dias-Filho CA, Ferreira AC, et al
    Carvacrol reduces blood pressure, arterial responsiveness and increases expression of MAS receptors in spontaneously hypertensive rats.
    Eur J Pharmacol. 2021 Dec 22:174717. doi: 10.1016/j.ejphar.2021.174717.
    PubMed     Abstract available
    
    
    
56. ZHENG L, Zhao Z, Lin J, Li H, et al
    Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction.
    Eur J Pharmacol. 2021 Dec 20:174713. doi: 10.1016/j.ejphar.2021.174713.
    PubMed     Abstract available
    
    
    
57. TOBA H, Ikemoto MJ, Kobara M, Nakata T, et al
    Secreted protein acidic and rich in cysteine (SPARC) and a disintegrin and metalloproteinase with thrombospondin type 1 motif (ADAMTS1) increments by the renin-angiotensin system induce renal fibrosis in deoxycorticosterone acetate-salt hypertensive r
    Eur J Pharmacol. 2021 Dec 3:174681. doi: 10.1016/j.ejphar.2021.174681.
    PubMed     Abstract available
    
    
    November 2021
58. KODAMA T, Kameshima S, Otani K, Okada M, et al
    Eukaryotic elongation factor 2 kinase inhibitor, A484954 induces diuretic effect via renal vasorelaxation in spontaneously hypertensive rats.
    Eur J Pharmacol. 2021 Nov 18:174637. doi: 10.1016/j.ejphar.2021.174637.
    PubMed     Abstract available
    
    
    October 2021
59. BALERA BRITO VG, Patrocinio MS, Alves Barreto AE, Tfaile Frasnelli SC, et al
    Telmisartan impairs the in vitro osteogenic differentiation of mesenchymal stromal cells from spontaneously hypertensive male rats.
    Eur J Pharmacol. 2021;912:174609.
    PubMed     Abstract available
    
    
    September 2021
60. ALVES BARRETO AE, Balera Brito VG, Patrocinio MS, Ballassoni BB, et al
    beta1-adrenergic receptor but not beta2 mediates osteogenic differentiation of bone marrow mesenchymal stem cells in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Sep 20:174515. doi: 10.1016/j.ejphar.2021.174515.
    PubMed     Abstract available
    
    
    
61. CORBOZ MR, Plaunt AJ, Malinin V, Li Z, et al
    Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Eur J Pharmacol. 2021 Sep 8:174484. doi: 10.1016/j.ejphar.2021.174484.
    PubMed     Abstract available
    
    
    
62. BADZYNSKA B, Vaneckova I, Sadowski J, Hojna S, et al
    Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Sep 4:174445. doi: 10.1016/j.ejphar.2021.174445.
    PubMed     Abstract available
    
    
    August 2021
63. HU J, Yang Z, Chen X, Kuang S, et al
    Thromboxane A2 is involved in the development of hypertension in chronic kidney disease rats.
    Eur J Pharmacol. 2021 Aug 17:174435. doi: 10.1016/j.ejphar.2021.174435.
    PubMed     Abstract available
    
    
    
64. ARAUJO ENCINAS JF, Foncesca Peiro CH, Perez MM, Santos Raimundo JR, et al
    Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review.
    Eur J Pharmacol. 2021;905:174180.
    PubMed     Abstract available
    
    
    July 2021
65. HUANG N, Zhu TT, Liu T, Ge XY, et al
    Aspirin ameliorates pulmonary vascular remodeling in pulmonary hypertension by dampening endothelial-to-mesenchymal transition.
    Eur J Pharmacol. 2021;908:174307.
    PubMed     Abstract available
    
    
    
66. BATISTA RIM, Nogueira RC, Ferreira GC, Oliveira-Paula GH, et al
    Antiseptic mouthwash inhibits antihypertensive and vascular protective effects of L-arginine.
    Eur J Pharmacol. 2021;907:174314.
    PubMed     Abstract available
    
    
    
67. LV Y, Ma P, Wang J, Xu Q, et al
    Betaine alleviates right ventricular failure via regulation of Rho A/ROCK signaling pathway in rats with pulmonary arterial hypertension.
    Eur J Pharmacol. 2021 Jul 7:174311. doi: 10.1016/j.ejphar.2021.174311.
    PubMed     Abstract available
    
    
    June 2021
68. ZHU JX, Ling W, Xue C, Zhou Z, et al
    Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-beta1/Smad signaling.
    Eur J Pharmacol. 2021;900:174013.
    PubMed     Abstract available
    
    
    May 2021
69. BUNBUPHA S, Prasarttong P, Poasakate A, Maneesai P, et al
    Imperatorin alleviates metabolic and vascular alterations in high-fat/high-fructose diet-fed rats by modulating adiponectin receptor 1, eNOS, and p47(phox) expression.
    Eur J Pharmacol. 2021;899:174010.
    PubMed     Abstract available
    
    
    
70. DOGHRI Y, Dubreil L, Lalanne V, Helissen O, et al
    Soluble guanylate cyclase chronic stimulation effects on cardiovascular reactivity in cafeteria diet-induced rat model of metabolic syndrome.
    Eur J Pharmacol. 2021;899:173978.
    PubMed     Abstract available
    
    
    April 2021
71. SILVA EAP, Carvalho JS, Dos Santos DM, Oliveira AMS, et al
    Cardiovascular effects of farnesol and its beta-cyclodextrin complex in normotensive and hypertensive rats.
    Eur J Pharmacol. 2021 Apr 2:174060. doi: 10.1016/j.ejphar.2021.174060.
    PubMed     Abstract available
    
    
    March 2021
72. POORGOLIZADEH E, Homayouni Moghadam F, Dormiani K, Rezaei N, et al
    Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!
    Eur J Pharmacol. 2021;894:173851.
    PubMed     Abstract available
    
    
    February 2021
73. ZHANG Y, Luo W, Li H, Yu G, et al
    Larger endothelium-dependent contractions in iliac arteries of adult SHRs are attributed to differential downregulation of TP and EP3 receptors in the vessels of WKYs and SHRs during the transition from adolescence to adulthood.
    Eur J Pharmacol. 2021;893:173828.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge.